Toxicity profile of main dual-targeting CAR products for B-cell lymphoma
| Reference . | Grading system used . | Total n . | CRS . | Neurotoxicity (ICANS) . | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Grade 1 . | Grade 2 . | Grade 3 . | Grade 4 . | Grade 5 . | Grade 1 . | Grade 2 . | Grade 3 . | Grade 4 . | Grade 5 . | |||
| Sang et al51 | ASTCT | 21 | 15 (71%) | 6 (29%) | — | 3 (14%) | 2 (10%) | — | ||||
| Larson et al73 | ASTCT | 10 | 6 (60%) | 0 | 0 | 0 | — | 0 | 0 | 0 | 0 | — |
| Shah et al74 | ASTCT CTCAE∗ | 22 | 13 (59%) | 1 (4%) | — | 4 (18%) | 3 (14%) | 0 | ||||
| Tong et al76 Zhang et al77 | ASTCT | 87 | 39 (45%) | 13 (15%) | 8 (9%) | 1 (1%) | — | 11 (13%) | 2 (2%) | 2 (2%) | 0 | — |
| Cao et al52 | ASTCT CTCAE∗ | 42 | 26 (62%) | 12 (29%) | 2 (5%) | 0 | — | 5 (12%) | 2 (5%) | 2 (5%) | 0 | 0 |
| Wu et al78 | ASTCT | 13 | 9 (69%) | 2 (15%) | 0 | 0 | — | 2 (15%) | 0 | 1 (8%) | 0 | — |
| Roddie et al79 | ASTCT | 52 | 11 (21%) | 7 (13%) | 1 (2%) | 0 | — | 2 (4%) | 2 (4%) | 0 | ||
| Spiegel et al62 | ASTCT CTCAE∗ | 21 | 12 (57%) | 3 (14%) | 1 (5%) | 0 | — | 5 (24%) | 3 (14%) | 1 (5%) | 0 | 0 |
| Wei et al80 | ASTCT | 16 | 4 (25%) | 11 (69%) | 0 | 1 (6%) | — | 0 | 0 | 0 | 0 | — |
| Zhang et al81 | CTCAE | 32 | 14 (44%) | 6 (19%) | 5 (16%) | 3 (9%) | 1 (3%) | 1 (3%) | 0 | 4 (13%) | 0 | 0 |
| Zhang et al82 | CTCAE | 16 | 7 (44%) | 0 | 1 (6%) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Reference . | Grading system used . | Total n . | CRS . | Neurotoxicity (ICANS) . | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Grade 1 . | Grade 2 . | Grade 3 . | Grade 4 . | Grade 5 . | Grade 1 . | Grade 2 . | Grade 3 . | Grade 4 . | Grade 5 . | |||
| Sang et al51 | ASTCT | 21 | 15 (71%) | 6 (29%) | — | 3 (14%) | 2 (10%) | — | ||||
| Larson et al73 | ASTCT | 10 | 6 (60%) | 0 | 0 | 0 | — | 0 | 0 | 0 | 0 | — |
| Shah et al74 | ASTCT CTCAE∗ | 22 | 13 (59%) | 1 (4%) | — | 4 (18%) | 3 (14%) | 0 | ||||
| Tong et al76 Zhang et al77 | ASTCT | 87 | 39 (45%) | 13 (15%) | 8 (9%) | 1 (1%) | — | 11 (13%) | 2 (2%) | 2 (2%) | 0 | — |
| Cao et al52 | ASTCT CTCAE∗ | 42 | 26 (62%) | 12 (29%) | 2 (5%) | 0 | — | 5 (12%) | 2 (5%) | 2 (5%) | 0 | 0 |
| Wu et al78 | ASTCT | 13 | 9 (69%) | 2 (15%) | 0 | 0 | — | 2 (15%) | 0 | 1 (8%) | 0 | — |
| Roddie et al79 | ASTCT | 52 | 11 (21%) | 7 (13%) | 1 (2%) | 0 | — | 2 (4%) | 2 (4%) | 0 | ||
| Spiegel et al62 | ASTCT CTCAE∗ | 21 | 12 (57%) | 3 (14%) | 1 (5%) | 0 | — | 5 (24%) | 3 (14%) | 1 (5%) | 0 | 0 |
| Wei et al80 | ASTCT | 16 | 4 (25%) | 11 (69%) | 0 | 1 (6%) | — | 0 | 0 | 0 | 0 | — |
| Zhang et al81 | CTCAE | 32 | 14 (44%) | 6 (19%) | 5 (16%) | 3 (9%) | 1 (3%) | 1 (3%) | 0 | 4 (13%) | 0 | 0 |
| Zhang et al82 | CTCAE | 16 | 7 (44%) | 0 | 1 (6%) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
ASTCT, American Society for Transplantation and Cellular Therapy; CRS, cytokine release syndrome; CTCAE, Common Terminology Criteria for Adverse Events; ICANS, immune effector cell–associated neurotoxicity syndrome.
Neurotoxicity graded by CTCAE in these studies.